IN THE CLAIMS:

1. A liquid formulation comprising apixaban and a vehicle,

the vehicle comprising water and at least two solubilizers selected from the group consisting of a non-ionic surfactant, an ionic surfactant, a hydrophilic polymer, ethanol, a polyhydric alcohol, a polyethylene glycol, and a carbohydrate,

wherein a solubility of apixaban in the vehicle is at least 0.50 mg/mL.

2. The liquid formulation of claim 1, wherein the solubility of apixaban in the vehicle is at least 0.60 mg/mL.

3. The liquid formulation of claim 1 or 2, wherein the solubility of apixaban in the vehicle is about 0.70 mg/mL to about 0.74 mg/mL.

4. The liquid formulation of any of claims 1 to 3, wherein:

water content of the vehicle is about 20% to about 30% w/w of the vehicle;

non-ionic surfactant content of the vehicle is about 11% to about 14% w/w of the vehicle;

ionic surfactant content of the vehicle is 0% to about 1% w/w of the vehicle;

hydrophilic polymer content of the vehicle is about 1% to about 6% w/w of the vehicle;

polyhydric alcohol content of the vehicle is about 31% to about 37% w/w of the vehicle;

polyethylene glycol content of the vehicle is about 4% to about 6% w/w of the vehicle; and

carbohydrate content of the vehicle is about 18% to about 22% w/w of the vehicle.

5. The liquid formulation of any of claims 1 to 4, wherein:

water content of the vehicle is about 23% to about 27% w/w of the vehicle;

non-ionic surfactant content of the vehicle is about 11.5% to about 13.5% w/w of the vehicle;

ionic surfactant content of the vehicle is about 0.2% to about 0.8% w/w of the vehicle;

hydrophilic polymer content of the vehicle is about 2% to about 5% w/w of the vehicle;

polyhydric alcohol content of the vehicle is about 32% to about 36% w/w of the vehicle;

polyethylene glycol content of the vehicle is about 4.5% to about 5.5% w/w of the vehicle; and

carbohydrate content of the vehicle is about 19% to about 21% w/w of the vehicle.

6. The liquid formulation of any of claims 1 to 5, wherein:

water content of the vehicle is about 23.5% to about 26% w/w of the vehicle;

non-ionic surfactant content of the vehicle is about 12% to about 13% w/w of the vehicle;

ionic surfactant content of the vehicle is about 0.4% to about 0.6% w/w;

hydrophilic polymer content of the vehicle is about 2.2% to about 4.2% w/w of the vehicle;

polyhydric alcohol content of the vehicle is about 33% to about 35% w/w of the vehicle;

polyethylene glycol content of the vehicle is about 4.8% to about 5.2% w/w of the vehicle; and

carbohydrate content of the vehicle is about 19.8% to about 20.2% w/w.

7. The liquid formulation of any of claims 1 to 3, comprising:

glycerin, at 0% to about 30% w/w of the vehicle;

propylene glycol, at 0% to about 20% w/w of the vehicle;

polyethylene glycol, at 0% to about 20% w/w of the vehicle;

polysorbate, at 0% to about 20% w/w of the vehicle;

povidone, at 0% to about 7% w/w of the vehicle;

sorbitol, at 0% to about 30% w/w of the vehicle;

sodium lauryl sulfate, at 0% to about 2% w/w of the vehicle;
copovidone, at 0% to about 7% w/w of the vehicle;
poloxamer, at 0% to about 7% w/w of the vehicle;
fructose, at 0% to about 30% w/w of the vehicle, and
sucrose, at 0% to about 30% w/w of the vehicle.

8. The liquid formulation of claim 7, comprising:
glycerin, at about 15% to about 25% w/w of the vehicle;
propylene glycol, at about 7% to about 20% w/w of the vehicle;
polyethylene glycol, at about 2% to about 7% w/w of the vehicle;
polysorbate, at about 5% to about 18% w/w of the vehicle;
povidone, at about 2% to about 5% w/w of the vehicle;
sorbitol, at about 15% to about 25% w/w of the vehicle;
sodium lauryl sulfate, at about 0.25% to about 1% w/w of the vehicle;
copovidone, at about 2% to about 5% w/w of the vehicle;
poloxamer, at about 2% to about 7% w/w of the vehicle;
fructose, at about 15% to about 25% w/w of the vehicle; and
sucrose, at about 15% to about 25% w/w of the vehicle.

9. The liquid formulation of any one of claims 1 to 6, wherein the non-ionic surfactant is selected from the group consisting of polyoxyethylene sorbitan fatty acid ester, poloxamer, polyoxyethylene castor oil derivative, polyoxyglyceride, vitamin E polyethylene glycol succinate, and macrogol 15 hydroxystearate.

10. The liquid formulation of any one of claims 1 to 6, wherein the ionic surfactant is selected from the group consisting of sodium lauryl sulfate and docusate sodium.

11. The liquid formulation of any one of claims 1 to 6, wherein the hydrophilic polymer is selected from the group consisting of povidone and copovidone.

12. The liquid formulation of any one of claims 1 to 6, wherein the polyhydric alcohol is selected from the group consisting of glycerin, propylene glycol, sorbitol, and mannitol.

13. The liquid formulation of any one of claims 1 to 6, wherein the carbohydrate is selected from the group consisting of fructose and sucrose.

14. The liquid formulation of any of claims 1 to 13, further comprising a flavoring agent, a sweetener, a preservative, a buffer, or any combination thereof.

15. A liquid formulation of any one of claims 1 to 14 that is suitable for oral administration.

16. A liquid formulation of any one of claims 1 to 15 that is suitable for administration through a nasogastric tube.

17. A method of administering a pharmaceutical composition, wherein the method comprises administering a dose of the pharmaceutical composition comprising apixaban in an orally acceptable liquid formulation, wherein the dose is less than 30 milliliters and is administered at least once daily.

18. The method of administering of claim 17, wherein apixaban has a solubility of at least 0.50 mg/mL.

19. The method of administering of claim 17 or 18, wherein apixaban has a solubility of at least 0.60 mg/mL.

20. The method of administering of any of claims 17 to 19, wherein apixaban has a solubility of at least 0.64 mg/mL.

21. The method of administering of any of claims 17 to 20, wherein apixaban has a solubility of at least 0.70 mg/mL.

22. The method of administering of any of claims 17 to 21, wherein apixaban has a solubility of at least 0.74 mg/mL.

23. The method of administering of any of claims 17 to 22, wherein apixaban is present in a concentration less than about 0.8 mg/mL.

24. The method of administering of any of claims 17 to 23, wherein a concentration of apixaban in the pharmaceutical composition is from about 0.3 mg/mL to about 0.5 mg/ml.

25. The method of administering of any of claims 17 to 24, wherein a concentration of apixaban in the pharmaceutical composition is about 0.3 mg/mL.

26. The method of administering of any of claims 17 to 24, wherein a concentration of apixaban in the pharmaceutical composition is about 0.4 mg/mL.

27. The method of administering of any of claims 17 to 24, wherein a concentration of apixaban in the pharmaceutical composition is about 0.5 mg/mL.

28. The method of administering of any of claims 17 to 27, wherein the dose is less than or equal to about 25 mL.

29. The method of administering of any of claims 17 to 28, wherein the dose is less than or equal to about 20 mL.

30. The method of administering of any of claims 17 to 29, wherein the dose is less than or equal to about 15 mL.

31. The method of administering of any of claims 17 to 30, wherein the dose is less than or equal to about 12.5 mL.

32. The method of administering of any of claims 17 to 31, wherein the dose is less than or equal to about 10 mL.

33. The method of administering of any of claims 17 to 32, wherein the dose is less than or equal to about 5 mL.

34. The method of administering of any of claims 17 to 33, wherein the dose is less than or equal to about 2.5 mL.

35. The method of administering of any of claims 17 to 34, wherein the dose is less than or equal to about 1 mL.

36. The method of administering of any of claims 17 to 35, wherein the dose is less than or equal to about 0.5 mL.

37. The method of administering of any of claims 17 to 36, wherein the dose has a pK profile for apixaban with a C_{max} of about 120 ng·h/mL to about 287 ng·h/mL.

38. The method of administering of any of claims 17 to 37, wherein the dose has a pK profile for apixaban with a C_{max} of about 120 ng·h/mL to about 287 ng·h/mL and a T_{max} of about 0.5 hours to about 4 hours post dose administration.

39. The method of administering of any of claims 17 to 38, wherein the dose is administered twice daily.

40. The method of administering of any of claims 17 to 39, wherein the liquid formulation includes water.

41. The method of administering of any of claims 17, 18, or 23 to 40,

wherein the liquid formulation comprises a vehicle comprising water and at least two solubilizers selected from the group consisting of a non-ionic surfactant, an ionic surfactant, a hydrophilic polymer, ethanol, a polyhydric alcohol, a polyethylene glycol, and a carbohydrate,

wherein apixaban has a solubility of at least 0.50 mg/mL.

42. The method of administering of any of claims 17 to 41, wherein the composition comprises about 1 mg of apixaban.

43. The method of administering of any of claims 17 to 41, wherein the composition comprises about 2.5 mg of apixaban.

44. The method of administering of any of claims 17 to 41, wherein the composition comprises about 5.0 mg of apixaban.

45. A liquid apixaban formulation comprising apixaban and an oral pharmaceutically acceptable liquid vehicle, wherein the formulation is substantially free of apixaban crystals.

46. The liquid apixaban formulation of claim 45, wherein the formulation is stable for a period of 2 years at room temperature.

47. The liquid apixaban formulation of claim 45 or 46, wherein the formulation is stable at 40°C for 3 months.

48. The liquid apixaban formulation of any of claims 45 to 47, wherein apixaban has a solubility of at least 0.50 mg/mL.

49. The liquid apixaban formulation of any of claims 45 to 48, wherein apixaban has a solubility of at least 0.60 mg/mL.

50. The liquid apixaban formulation of any of claims 45 to 49, wherein apixaban has a solubility of at least 0.70 mg/mL.

51. The liquid apixaban formulation of any of claims 45 to 50, wherein apixaban has a solubility of at least 0.74 mg/mL.

52. The liquid apixaban formulation of any of claims 45 to 51, wherein a concentration of apixaban in the formulation is less than about 0.8 mg/mL.

53. The liquid apixaban formulation of any of claims 45 to 52, wherein a concentration of apixaban in the formulation is from about 0.3 mg/mL to about 0.5 mg/mL.